Correlation between healthy vascular aging and prevalent cardiovascular disease risk in middle-aged and elderly people in the community of Shanghai

doi:10.3969/j.issn.1674-8115.2021.02.015

Abstract

Abstract: Objective

·To study the correlation between healthy vascular aging (HVA) and prevalent cardiovascular diseases (CVDs) risk in middle-aged and elderly people in the community of Shanghai.

Methods

·A total of 9 922 participants aged 40 and above who lived in a Jiading community of Shanghai were included. The questionnaire interview, physical examination, biochemical index detection and brachial-ankle pulse wave velocity (baPWV) measurement were conducted in all participants. According to HVA status, the participants were divided into HVA group and non-HVA group. HVA was defined as baPWV≤15.20 m/s with no history of hypertension. The CVDs include stroke, myocardial infarction and coronary atherosclerotic heart disease. Logistic regression model was used to analyze the correlation between HVA and prevalent CVDs risk.

Results

·Compared with those in the non-HVA group, the age, body mass index, systolic blood pressure, diastolic blood pressure, total cholesterol, low density lipoprotein-cholesterol, fasting blood glucose, serum creatinine, baPWV and prevalence of diabetes mellitus and lipid disorders in the HVA group were lower, and the proportion of education level (high school or above) and estimated glomerular filtration rate in the HVA group were higher in both men and women (all P=0.000). Logistic regression analysis showed that after multiple confounding factors being adjusted, prevalent CVDs risk in the HVA group was significantly lower than that in the non-HVA group (OR=0.53, 95%CI 0.41?0.69, P=0.000).

Conclusions

·HVA is significantly associated with a lower risk of CVDs in middle-aged and elderly people (aged≥40) in the community of Shanghai, which suggests that HVA can be used as a potential indicator of CVDs prevention.

Key words: healthy vascular aging (HVA), cardiovascular disease (CVD), middle-aged and elderly people

CLC Number:

R543.5

Hua-jie DAI, Li-ping XUAN, Jia-li XIANG, Hong LIN, Zhi-yun ZHAO, Tian-ge WANG, Mian LI, Yu XU, Jie-li LU, Wei-qing WANG, Yu-fang BI, Min XU. Correlation between healthy vascular aging and prevalent cardiovascular disease risk in middle-aged and elderly people in the community of Shanghai[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(2): 223-227.

Figures/Tables 3

TrendMD

References 21

1	Groenewegen KA, den Ruijter HM, Pasterkamp G, et al. Vascular age to determine cardiovascular disease risk: a systematic review of its concepts, definitions, and clinical applications[J]. Eur J Prev Cardiol, 2016, 23(3): 264-274.
2	Ji H, Teliewubai J, Lu Y, et al. Vascular aging and preclinical target organ damage in community-dwelling elderly: the Northern Shanghai Study[J]. J Hypertens, 2018, 36(6): 1391-1398.
3	Seals DR, Alexander LM. Vascular aging[J]. J Appl Physiol (1985), 2018, 125(6): 1841-1842.
4	Laurent S. Defining vascular aging and cardiovascular risk[J]. J Hypertens, 2012, 30Suppl: S3-S8.
5	Camici GG, Savarese G, Akhmedov A, et al. Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease[J]. Eur Heart J, 2015, 36(48): 3392-3403.
6	Lemogoum D, Ngatchou W, Janssen C, et al. Effects of hunter-gatherer subsistence mode on arterial distensibility in Cameroonian pygmies[J]. Hypertension, 2012, 60(1): 123-128.
7	Gurven M, Blackwell AD, Rodríguez DE, et al. Does blood pressure inevitably rise with age? Longitudinal evidence among forager-horticulturalists[J]. Hypertension, 2012, 60(1): 25-33.
8	Niiranen TJ, Lyass A, Larson MG, et al. Prevalence, correlates, and prognosis of healthy vascular aging in a western community-dwelling cohort: the Framingham heart study[J]. Hypertension, 2017, 70(2): 267-274.
9	Yang Y, Wang A, Yuan X, et al. Association between healthy vascular aging and the risk of the first stroke in a community-based Chinese cohort[J]. Aging (Albany NY), 2019, 11(15): 5807-5816.
10	Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate[J]. Ann Intern Med, 2009, 150(9): 604-612.
11	Chalmers J, MacMahon S, Mancia G, et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization[J]. Clin Exp Hypertens, 1999, 21(5-6): 1009-1060.
12	中国成人血脂异常防治指南制订联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志, 2007, 35(5): 390-419.
13	Gajra A, Zemla TJ, Jatoi A, et al. Time-to-treatment-failure and related outcomes among 1 000+ advanced non-small cell lung cancer patients: comparisons between older versus younger patients (alliance a151711)[J]. J Thorac Oncol, 2018, 13(7): 996-1003.
14	Nowak KL, Rossman MJ, Chonchol M, et al. Strategies for achieving healthy vascular aging[J]. Hypertension, 2018, 71(3): 389-402.
15	Rossman MJ, LaRocca TJ, Martens CR, et al. Healthy lifestyle-based approaches for successful vascular aging[J]. J Appl Physiol (1985), 2018, 125(6): 1888-1900.
16	Kucharska-Newton AM, Stoner L, Meyer ML. Determinants of vascular age: an epidemiological perspective[J]. Clin Chem, 2019, 65(1): 108-118.
17	Tanaka H, DeSouza CA, Seals DR. Absence of age-related increase in central arterial stiffness in physically active women[J]. Arterioscler Thromb Vasc Biol, 1998, 18(1): 127-132.
18	Tanaka H, Dinenno FA, Monahan KD, et al. Aging, habitual exercise, and dynamic arterial compliance[J]. Circulation, 2000, 102(11): 1270-1275.
19	Ahmadi-Abhari S, Sabia S, Shipley MJ, et al. Physical activity, sedentary behavior, and long-term changes in aortic stiffness: the Whitehall Ⅱ study[J]. J Am Heart Assoc, 2017, 6(8): e005974.
20	Strauss M, Smith W, Kruger R, et al. Large artery stiffness is associated with salt intake in young healthy black but not white adults: the African-PREDICT study[J]. Eur J Nutr, 2018, 57(7): 2649-2656.
21	Liu Y, Dai M, Bi Y, et al. Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): a population-based study in China[J]. J Epidemiol, 2013, 23(2): 115-121.

Item	Total (N=9 922)	Male			Female
Item	Total (N=9 922)	Non-HVA group (N=2 746)	HVA group (N=1 026)	P value	Non-HVA group (N=4 173)	HVA group (N=1 977)	P value
Basic information
Age/year	58.5±9.6	61.0±9.8	53.4±7.9	0.000	60.9±9.2	52.6±7.3	0.000
Education level (high school or above)^①/n(%)	2 132 (21.58)	647 (23.66)	302 (29.52)	0.000	602 (14.51)	581 (29.48)	0.000
Current smoking^①/n(%)	1 995 (20.33)	1 301 (47.45)	668 (65.17)	0.000	14 (0.34)	12 (0.62)	0.127
Current drinking^①/n(%)	987 (10.28)	700 (26.02)	240 (23.81)	0.169	30 (0.75)	17 (0.90)	0.552
Active physical activity/n(%)	1 924 (19.39)	615 (22.40)	220 (21.44)	0.530	740 (17.73)	349 (17.65)	0.939
Physical examination index
BMI/(kg·m^-2)	25.1±3.3	25.5±3.1	24.2±2.9	0.000	25.5±3.4	23.8±3.0	0.000
SBP/mmHg	141.1±20.0	147.8±17.0	123.0±9.6	0.000	150.5±17.7	121.6±10.0	0.000
DBP/mmHg	82.8±10.3	87.1±10.1	77.6±6.8	0.000	84.7±10.2	75.4±7.0	0.000
Biochemical index
TAG/(mmol·L^-1)	1.4 (1.0, 2.0)	1.4 (1.0, 2.0)	1.3 (0.9, 1.8)	0.058	1.5 (1.1, 2.1)	1.1 (0.8, 1.6)	0.002
TC/(mmol·L^-1)	5.3±1.0	5.2±1.0	5.0±0.9	0.000	5.6±1.0	5.3±0.9	0.000
LDL-Ch/(mmol·L^-1)	3.2±0.9	3.1±0.8	2.9±0.8	0.000	3.4±0.9	3.1±0.8	0.000
HDL-Ch/(mmol·L^-1)	1.3±0.3	1.2±0.3	1.2±0.3	0.815	1.4±0.3	1.4±0.3	0.000
FBG/(mmol·L^-1)	5.6±1.5	5.8±1.7	5.4±1.5	0.000	5.7±1.6	5.1±0.8	0.000
Scr/(μmol·L^-1)	61.9±17.5	73.4±20.4	70.8±10.0	0.000	56.1±15.2	53.8±7.6	0.000
eGFR/ [mL·(min·1.73 m2)^-1]	109.3±21.3	105.0±21.3	110.2±18.6	0.000	109.0±22.2	115.6±19.3	0.000
Diabetes mellitus/n(%)	1 798 (18.12)	647 (23.56)	116 (11.31)	0.000	914 (21.90)	121 (6.12)	0.000
Dyslipidemia^①/n(%)	3 982 (40.14)	1 232 (44.87)	391 (38.15)	0.000	1 848 (44.28)	511 (25.85)	0.000
baPWV/(m·s^-1)	16.2±3.7	17.3±3.5	13.2±1.1	0.000	17.7±3.7	12.9±1.3	0.000

Item	Total (N=9 922)	Male			Female
Item	Total (N=9 922)	Non-HVA group (N=2 746)	HVA group (N=1 026)	P value	Non-HVA group (N=4 173)	HVA group (N=1 977)	P value
Basic information
Age/year	58.5±9.6	61.0±9.8	53.4±7.9	0.000	60.9±9.2	52.6±7.3	0.000
Education level (high school or above)^①/n(%)	2 132 (21.58)	647 (23.66)	302 (29.52)	0.000	602 (14.51)	581 (29.48)	0.000
Current smoking^①/n(%)	1 995 (20.33)	1 301 (47.45)	668 (65.17)	0.000	14 (0.34)	12 (0.62)	0.127
Current drinking^①/n(%)	987 (10.28)	700 (26.02)	240 (23.81)	0.169	30 (0.75)	17 (0.90)	0.552
Active physical activity/n(%)	1 924 (19.39)	615 (22.40)	220 (21.44)	0.530	740 (17.73)	349 (17.65)	0.939
Physical examination index
BMI/(kg·m^-2)	25.1±3.3	25.5±3.1	24.2±2.9	0.000	25.5±3.4	23.8±3.0	0.000
SBP/mmHg	141.1±20.0	147.8±17.0	123.0±9.6	0.000	150.5±17.7	121.6±10.0	0.000
DBP/mmHg	82.8±10.3	87.1±10.1	77.6±6.8	0.000	84.7±10.2	75.4±7.0	0.000
Biochemical index
TAG/(mmol·L^-1)	1.4 (1.0, 2.0)	1.4 (1.0, 2.0)	1.3 (0.9, 1.8)	0.058	1.5 (1.1, 2.1)	1.1 (0.8, 1.6)	0.002
TC/(mmol·L^-1)	5.3±1.0	5.2±1.0	5.0±0.9	0.000	5.6±1.0	5.3±0.9	0.000
LDL-Ch/(mmol·L^-1)	3.2±0.9	3.1±0.8	2.9±0.8	0.000	3.4±0.9	3.1±0.8	0.000
HDL-Ch/(mmol·L^-1)	1.3±0.3	1.2±0.3	1.2±0.3	0.815	1.4±0.3	1.4±0.3	0.000
FBG/(mmol·L^-1)	5.6±1.5	5.8±1.7	5.4±1.5	0.000	5.7±1.6	5.1±0.8	0.000
Scr/(μmol·L^-1)	61.9±17.5	73.4±20.4	70.8±10.0	0.000	56.1±15.2	53.8±7.6	0.000
eGFR/ [mL·(min·1.73 m2)^-1]	109.3±21.3	105.0±21.3	110.2±18.6	0.000	109.0±22.2	115.6±19.3	0.000
Diabetes mellitus/n(%)	1 798 (18.12)	647 (23.56)	116 (11.31)	0.000	914 (21.90)	121 (6.12)	0.000
Dyslipidemia^①/n(%)	3 982 (40.14)	1 232 (44.87)	391 (38.15)	0.000	1 848 (44.28)	511 (25.85)	0.000
baPWV/(m·s^-1)	16.2±3.7	17.3±3.5	13.2±1.1	0.000	17.7±3.7	12.9±1.3	0.000

Gender	Age<65 years			Age≥65 years
Gender	Prevalence in HVA group/%	Prevalence in non-HVA group/%	P value	Prevalence in HVA group/%	Prevalence in non-HVA group/%	P value
Male	2.1	6.6	0.000	12.1	18.1	0.154
Female	2.9	7.6	0.000	8.9	16.5	0.044

Gender	Age<65 years			Age≥65 years
Gender	Prevalence in HVA group/%	Prevalence in non-HVA group/%	P value	Prevalence in HVA group/%	Prevalence in non-HVA group/%	P value
Male	2.1	6.6	0.000	12.1	18.1	0.154
Female	2.9	7.6	0.000	8.9	16.5	0.044

Model	Total		Male		Female		Age<65 years		Age≥65 years
Model	OR (95%CI)	Pvalue	OR (95%CI)	Pvalue	OR (95%CI)	Pvalue	OR (95%CI)	Pvalue	OR (95%CI)	Pvalue
Model 1	0.56 (0.44?0.70)	0.000	0.55 (0.37?0.83)	0.004	0.55 (0.41?0.74)	0.000	0.51 (0.39?0.67)	0.000	0.75 (0.46?1.21)	0.239
Model 2	0.55 (0.43?0.70)	0.000	0.57 (0.38?0.86)	0.007	0.53 (0.40?0.72)	0.000	0.51 (0.39?0.67)	0.000	0.76 (0.47?1.24)	0.274
Model 3	0.53 (0.41?0.69)	0.000	0.55 (0.35?0.84)	0.006	0.52 (0.38?0.73)	0.000	0.45 (0.33?0.62)	0.000	0.82 (0.49?1.37)	0.446